RBC Capital Markets has lowered its price target for Legend Biotech from $56 to $50, while simultaneously reaffirming its Outperform rating. This adjustment follows the company's Q3 2026 financial results, suggesting a re-evaluation of future growth prospects or valuation metrics by the analyst.
RBC Capital Markets has reduced its price target for Legend Biotech (LEGN) from $56 to $50. This move, despite maintaining an 'Outperform' rating, signals a potential recalibration of the company's valuation by a key analyst following its Q3 2026 earnings. While the maintained 'Outperform' rating suggests continued confidence in the company's long-term prospects, the lower price target could lead to short-term negative sentiment or a slight downward pressure on the stock as investors digest the revised outlook. For traders, this presents a nuanced situation: a potential dip could be seen as a buying opportunity by those who align with the 'Outperform' rating, while others might view it as a signal to re-evaluate their positions.